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Abstract: Tolvaptan is a selective arginine vasopressin (AVP) V2 receptor blocker used to induce 
free water diuresis in the treatment of euvolemic or hypervolemic hyponatremia. Currently the 
orally active medication is in the ﬁ  nal stages prior to approval by the FDA for outpatient therapy. 
It appears to be safe and effective at promoting aquaresis and raising serum sodium levels in 
both short- and long-term studies. Tolvaptan is also effective for treatment of congestive heart 
failure (CHF) exacerbation, but whether there are long standing beneﬁ  cial effects on CHF is 
still controversial. Prolonged use of tolvaptan leads to increased endogenous levels of AVP and 
perhaps over-stimulation of V1A receptors. Theoretically this activation could lead to increased 
afterload and cardiac myocyte ﬁ  brosis, causing progression of CHF. However, after 52 weeks of 
tolvaptan therapy there was no worsening of left ventricular dilatation. In addition, tolvaptan is 
metabolized by the CYP3A4 system; thus physicians should be aware of the potential for increased 
interactions with other medications. Tolvaptan is a breakthrough in the therapy of hyponatremia as 
it directly combats elevated AVP levels associated with the syndrome of inappropriate secretion 
of antidiuretic hormone, congestive heart failure, and cirrhosis of the liver.
Keywords: hyponatremia, arginine vasopressin, vasopressin receptors, syndrome of 
inappropriate antidiuretic hormone, congestive heart failure, liver cirrhosis
Introduction
Volume overload and hyponatremia cause signiﬁ  cant morbidity and may lead to increased 
mortality in patients with the syndrome of inappropriate antidiuretic hormone (SIADH), 
congestive heart failure (CHF), and liver cirrhosis (Lee et al 2003). Elevated levels of 
arginine vasopressin (AVP or antidiuretic hormone) contribute to this state of total body 
water excess and hyponatremia (Goldsmith et al 1983). Diuretics and free water restriction 
have historically been used to combat this condition but have unwanted side effects 
including electrolyte imbalances, arrhythmias, and renal failure. Vasopressin receptor 
antagonists (VRAs or “vaptans”) directly target stimulated AVP receptors in the collecting 
duct of the kidney, down-regulating aquaporin insertion and free water absorption. 
Tolvaptan, an oral V2-receptor speciﬁ  c antagonist, has been very effective and safe in 
outpatient trials in treating hyponatremia and volume overload. It was recently approved 
by the EMEA (European Medicines Agency) for use in Europe. The US FDA has recom-
mended tolvaptan for the treatment of hyponatremia, but it is currently not approved for 
use in the US. Presently, only intravenous conivaptan has been approved by the FDA for 
the short-term treatment (4 days) of hyponatremia in hospitalized patients. Unfortunately, 
the lack of follow-up therapy signiﬁ  cantly limits the usage of conivaptan. An efﬁ  cacious 
oral agent would be ideal for the outpatient management of chronic hyponatremia.
Regulation of vasopressin
AVP or antidiuretic hormone (ADH) is produced in the hypothalamus and delivered 
to the posterior pituitary for release into systemic circulation. Secretion of AVP is Therapeutics and Clinical Risk Management 2008:4(6) 1150
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mediated by several mechanisms. Osmotic pressure is the 
most sensitive stimulus for AVP release and is mediated by 
osmoreceptors in the hypothalmus. Sodium concentration 
greatly inﬂ  uences osmotic pressure. A decrease in osmolality 
as minimal as 1% to 2% rapidly suppresses AVP secretion 
and induces aquaresis. Arterial pressure reduction also stimu-
lates AVP release, but typically there must be a signiﬁ  cant 
reduction of 10% to 20% as sensed by baroreceptors in the 
left atrium and aorta. It appears that arterial pressure provokes 
AVP release by lowering the set point of the osmoregulatory 
system (Schrier 2007). Heart failure and cirrhosis cause an 
arterial underﬁ  lling, stimulating AVP release, and overriding 
hypo-osmolality-induced AVP inhibition (Lien and Shapiro 
2007). The result is hyponatremia in the face of total body 
volume overload. As for SIADH, the excessive release of 
vasopressin is independent of osmolality and volume status. 
Patients exhibit mild volume overload due to water retention 
and signiﬁ  cant hyponatremia as a consequence.
Vasopressin receptors
AVP stimulates both V1A and V2 receptors. V1A receptors 
are located in vascular smooth muscle and cause arterial 
vasoconstriction to compensate for low arterial pressure. 
AVP exerts its anti-diuretic effect by stimulating the V2 
receptor located on the basolateral side of the principal 
cell in the cortical collecting duct. AVP V2 is a G protein-
coupled receptor, which when stimulated initiates adenylate 
cyclase and leads to increased intracellular cAMP (Lien 
and Shapiro 2007). Elevated cAMP signals placement of 
vesicle-encased aquaporin-2 channels in the principal cell 
apical membrane, facilitating free water absorption in the 
collecting tubule. Most of  the “vaptans,” including tolvaptan, 
are V2 receptor-selective, except conivaptan, which blocks 
both receptors.
Pharmacological actions 
of tolvaptan
Tolvaptan (study name OPC-41061) is an orally active, 
non-peptide, selective V2 receptor antagonist that blocks 
AVP binding and promotes free water excretion. The 
comparisons and interactions between VRAs and diuretics 
are clinically important because diuretics are likely to be 
used in conjunction with tolvaptan. Shoaf et al (2007) 
performed a pilot, randomized, cross-over study to determine 
the pharmacologic interactions between tolvaptan and 
furosemide or hydroclorothiazide (HCTZ) (Shoaf et al 2007). 
Twelve healthy young Caucasian men were randomized to 
receive 30 mg of tolvaptan, then 80 mg of furosemide (6) or 
100 mg of HCTZ (6), and ﬁ  nally both medications together. 
A 48-hour washout period was observed between therapies. 
Multiple measurements were gathered including urinary 
output, electrolyte concentrations of plasma and urine, 
and neurohormone levels in addition to pharmacological 
parameters. Tolvaptan alone had a 50% increase in 24-hour 
urine output compared with furosemide and HCTZ (dosed 
once daily). Urinary sodium was 50% greater during 
furosemide and HCTZ therapy in comparison to tolvaptan. 
Kaluresis did not differ largely between drugs. Plasma 
levels of sodium increased during therapy with tolvaptan 
and decreased with furosemide and HCTZ. Renin activity 
was increased at 24 hours post dose for all patients treated 
with furosemide, HCTZ, or a combination of either with 
tolvaptan. Tolvaptan alone had negligible increases in renin 
activity but did show increased AVP levels at 24 hours. 
Despite increased AVP levels, blood pressure did not differ 
in patients treated with tolvaptan. Interestingly, the maximum 
tolvaptan concentration (Cmax) and area under the plasma 
concentration-time curve (AUC∞) was increased for tolvaptan 
plus furosemide, but urinary and hemodynamic parameters 
were unchanged. There was no additive effect with diuretic 
adjunct therapy in this study.
Tolvaptan for treating hyponatremia
SALT 1 and 2 (Study of Ascending Levels of Tolvaptan 
in Hyponatremia) were designed to focus speciﬁ  cally on 
changes in serum sodium in patients with hyponatremia 
from multiple disorders including SIADH, heart failure 
and cirrhosis (Shrier et al 2006). Two separate randomized, 
double-blind, placebo-controlled trials of 200 to 250 patients 
were performed to determine reproducibility. Patients were 
randomized to tolvaptan treatment (with dose adjustment 
from 15 to 60 mg as needed) versus placebo and treated 
for 30 days with follow-up assessment at 1 week post 
completion. The area-under-the-curve (AUC) for increase 
in sodium levels from baseline to day 4 and day 30 was 
significantly greater in the tolvaptan versus placebo 
treatment group (p  0.001). The average baseline serum 
sodium in both groups was 128 mmol/L. At day 4, tolvaptan-
treated patients had an average sodium of 134 and placebo 
130 mmol/L (p  0.001). Serum sodium rose to an average 
of 136 mmol/L in the tolvaptan group at day 30, but was 
unchanged in the placebo group. The greatest difference 
was in patients with marked hyponatremia. Side effects 
were minimal and included dry mouth and increased thirst. 
Overcorrection of hyponatremia (0.5 mmol/L/h) occurred 
in less than 2% of tolvaptan-treated patients, yet none Therapeutics and Clinical Risk Management 2008:4(6) 1151
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of them developed central pontine myelinolysis. Once 
tolvaptan was discontinued at day 30, serum sodium levels 
returned to similar levels or below those of their placebo 
counterparts.
Tolvaptan therapy versus fluid restriction for the 
treatment of hyponatremia was studied by Gheorghiade et al 
(2006). Twenty-eight hospitalized subjects with a serum 
sodium 135 mmol/L were randomized to tolvaptan alone 
(17) versus ﬂ  uid restriction of 1200 mL/day (11) for 27 days. 
Tolvaptan doses were increased from 15 to 60 mg/day as 
needed to increase serum sodium levels. The primary endpoint 
was normalization of serum sodium (135 mmol/L) or 
an increase 10% from baseline. Normalization of serum 
sodium occurred in 50% of patients by day 4 when treated 
with tolvaptan and by day 8 on ﬂ  uid restriction (p  0.03). 
Serum sodium increased 5.7 ± 3.2 mmol/L in the tolvaptan-
treated group and 1.0 ± 4.7 mmol/L in the ﬂ  uid-restriction 
group (p = 0.0065). Clearly tolvaptan showed superiority in 
treating hyponatremia compared with ﬂ  uid restriction alone. 
As patients are likely to be non-compliant with ﬂ  uid restriction, 
tolvaptan is likely to be very successful in outpatients.
Effects of tolvaptan on congestive 
heart failure: short-term effects
Congestive heart failure is a common cause of hyponatremia 
and associated with elevated AVP levels (Goldsmith 
et al 1983). Tolvaptan has largely been studied in the setting 
of CHF as a novel way to treat CHF exacerbations and 
perhaps alter the natural course of heart failure. Three major 
studies that investigated short-term effects of tolvaptan on 
CHF and related hyponatremia are summarized in Table 1.
Gheorghiade et al (2003) reported the ﬁ  rst randomized, 
double-blinded trial of tolvaptan in patients with symptomatic 
heart failure. In this study, 254 patients with NYHA class I, II 
or III CHF were randomly assigned to receive tolvaptan 30, 
45 or 60 mg versus placebo for 25 days. Patients were kept 
on stable doses of CHF ameliorating medications including 
angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers (ACE-I/ARB), beta-blockers, and 
furosemide and allowed to drink ﬂ  uids freely. Weight loss 
was approximately –0.8 kg for patients treated with tolvaptan 
(regardless of dose) versus a gain of +0.3 kg for placebo at 
day 1 (p  0.001 for all groups and placebo). Patients main-
tained this weight reduction at day 25 but did not lose further 
weight while on tolvaptan. Signiﬁ  cant aquaresis was noted in 
the tolvaptan groups in comparison to placebo. Urine output 
measured approximately 4 L/day on therapy with tolvaptan 
and only 2 L/day with placebo, while urine osmolality 
decreased in tolvaptan groups and increased in the placebo 
group. Hyponatremic enrollees had larger increases in serum 
sodium than normonatremic counterparts. Eighty-two percent 
of the hyponatremic tolvaptan enrollees attained a normal 
Table 1 Short-term effects of tolvaptan on congestive heart failure
Study Treatment Weight loss (kg) Weight loss (kg) Urine output 
(L/day)
Urine 
osmolality 
(mOsm/kg)
Change 
in Sna 
(meq/L)
Change in 
Sna (meq/L)
Day 1 Day 7 Day 1 Day 1 Day 1 Day 7
Tolvaptan in 
patients with CHF
Tolvaptan
30 mg
45 mg
60 mg
Placebo
0.79 ± 0.99
0.96 ± 0.93
0.84 ± 0.02
+0.32 ± 0.46
3.9 ± 0.6
4.2 ± 0.9
4.6 ± 0.4
2.3 ± 0.2
15.5 ± 190
52.4 ± 165
118.8 ± 132
+135.8 ± 189
ACTIV in CHF Tolvaptan
30 mg
60 mg
90 mg
Placebo
1.80 (−3.85 to −0.5)
2.10 (−3.1 to −0.85)
2.05 (−2.80 to −0.6)
0.60 (−1.60 to 0)
+2.77
+3.38
+3.50
0.20
EVEREST Tolvaptan 
30 mg
Trial A
Trial B
1.71 ± 1.8
1.82 ± 2.01
3.35 ± 3.3
3.77 ± 3.6
+3.28 +2.07
Placebo A
Placebo B
0.99 ± 1.83
0.95 ± 1.85
2.73 ± 3.3
2.79 ± 3.5
0.41 1.06
All above comparisons of tolvaptan versus placebo are statistically signiﬁ  cant (p  0.05).
Abbreviation: CHF, congestive heart failure.Therapeutics and Clinical Risk Management 2008:4(6) 1152
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serum sodium level by the end of the 25 days. Although not 
statistically signiﬁ  cant, AVP concentrations were higher in 
tolvaptan-treated patients than placebo. Again, there were 
no differences in blood pressure measurements between 
both groups.
Gheorghiade et al (2004) then launched a larger, 
randomized trial of tolvaptan in hospitalized patients 
with congestive failure exacerbation, the ACTIV in CHF 
investigation (Acute and Chronic Therapeutic Impact of 
a Vasopressin antagonist in Congestive Heart Failure). 
Three hundred nineteen patients with reduced ejection 
fraction (40%) and persistence of congestive symptoms 
despite standard therapy with diuretics were randomized 
to tolvaptatn 30 mg, 60 mg, 90 mg daily, or placebo for up 
to 60 days. Patients were continued on other CHF therapy 
including diuretics, ACE-I/ARB, and beta-blockers. The 
acute primary outcome was change in body weight at 
24 hours. Tolvaptan showed signiﬁ  cant decreases in mean 
body weight (regardless of dose) in comparison to placebo. 
Serum sodium increased by approximately 3 meq/L for 
tolvaptan-treated patients and decreased by −0.2 meq/L in 
the placebo group. Patients with underlying hyponatremia 
that were treated with tolvaptan often had a normalization 
of their serum sodium levels. At time of discharge, dyspnea 
scores were signiﬁ  cantly improved in the tolvaptan treatment 
arm (p = 0.04).
The third study was the EVEREST trial (Efﬁ  cacy of 
Vasopressin antagonism in Heart Failure Outcome Study 
with Tolvaptan), which also examined short- and long-term 
effects of tolvaptan therapy in patients with CHF exacerbation 
(Cheorghiade et al 2007). Two identical randomized, 
double-blinded, placebo-controlled trials (A and B) of 
2000+ patients with worsening heart failure symptoms were 
performed in North America, South America, and Europe. 
Patients were given appropriate therapy with diuretics, 
ACE-I/ARB, beta-blocker at the discretion of investigators 
and then randomized to receive 30 mg of tolvaptan versus 
placebo. Primary outcomes included body weight at day 7 or 
discharge (whichever came ﬁ  rst) and changes in clinical status 
measured with a visual analog scale. Weight reduction was 
signiﬁ  cantly reduced in patients treated with tolvaptan versus 
placebo at day 1 and day 7 or discharge (p  0.001 for all 
comparisons). Secondary outcomes, including self-reported 
dyspnea at day 1 and lower extremity edema evaluated by 
clinicians, were improved on tolvaptan (p  0.05 except 
edema evaluation in Trial A). Serum sodium elevated a mean 
of 3.3 meq/L at day 1 and remained elevated 2.0 meq/L at 
day 7 or discharge in tolvaptan-treated groups and dropped 
in placebo groups (p  0.001). The change in serum sodium 
was most impressive in patients with a baseline serum sodium 
134 meq/L at randomization. For this group, those receiving 
tolvaptan had a serum sodium increase of 5.5 meq/L at day 
7 or discharge, while those of placebo had an elevation of 
1.9 meq/L (p  0.001) (Konstam et al 2007). Despite signiﬁ  -
cantly more thirst and dry mouth in the tolvaptan groups there 
were no other differences in adverse effects. No increased 
incidence of hypotension, arrhythmia, renal failure, or 
electrolyte abnormality was noted in tolvaptan-treated patients. 
The short-term arm of EVEREST study complemented the 
results shown 3 years earlier in ACTIV in CHF.
The short-term effects of tolvaptan on renal hemodynamics 
in CHF patients have been compared with furosemide and 
placebo by Costello-Boerrigter et al (2005). The randomized, 
placebo-controlled crossover study investigated the changes 
in urine output, sodium and potassium excretion, renal 
blood ﬂ  ow (RBF), and glomerular ﬁ  ltration rate (GFR) in 
14 patients with stable class II or III heart failure and ejection 
fraction 40%. Patients received either tolvaptan 30 mg or 
placebo on day 1 and then were crossed to receive the other 
medication on day 3. Both groups then received 80 mg of 
furosemide on day 5 for comparison. All other CHF medi-
cations including maintenance ACE-I/ARB, beta-blockers, 
aspirin, and diuretics were held prior to the start of the study. 
Patients were maintained on similar sodium-restricted diets 
and were given water at prescribed points during the day. No 
raw data were available in the study text, but analysis noting 
statistical signiﬁ  cance was reported. Urine output increased 
signiﬁ  cantly with tolvaptan and furosemide treatment versus 
placebo, but there was no advantage between the two. Urinary 
sodium and potassium excretion was statistically greater in 
furosemide than in tolvaptan and placebo treatment. Urine 
osmolality was lowest in tolvaptan, signiﬁ  cantly reduced 
from placebo (p  0.05) but not from furosemide treatment 
(p = 0.10). Renal blood ﬂ  ow, measured by PAH clearance, 
was signiﬁ  cantly lower in furosemide therapy than tolvaptan 
and placebo. Renal blood ﬂ  ow actually was mildly increased 
from placebo (p = 0.19) in tolvaptan treatement. Finally, 
GFR (measured by inulin clearance) was similar between 
all three therapies. Neurohormonal measurements at 0.5 
and 2.5 hours after medication administration were also 
attained – AVP, renin, aldosterone, atrial natriuretic peptide, 
beta natriuretic peptide, and norepinephrine. AVP levels were 
similar among the three treatment groups (likely related to 
short duration of tolvaptan therapy), with only a signiﬁ  cant 
increase in plasma renin activity in furosemide versus placebo 
but not furosemide versus tolvaptan. The authors concluded Therapeutics and Clinical Risk Management 2008:4(6) 1153
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that tolvaptan was a safe aquaretic similar in efﬁ  cacy to 
furosemide therapy for mild to moderate CHF.
In summary, aquaresis and elevations in serum sodium, 
especially in hyponatremic patients, were well-documented in 
short-term investigations. There was no dose-related improve-
ment in weight loss, serum sodium increase, or CHF symptoms 
with escalating doses of tolvaptan. For that reason, a single 
dose of 30 mg daily was used for many subsequent studies.
Effects of tolvaptan on congestive 
heart failure: long-term effects
Long-term effects of tolvaptan on morbidity and mortality 
associated with CHF have not been validated. As mentioned 
earlier, both the ACTIV in CHF and the EVEREST studies 
examined long-term outcomes. In a third study, by Udelson 
et al (2005), left ventricular end diastolic volume (LVEDV) 
and other parameters were measured while on tolvaptan. The 
results of these three studies are summarized in Table 2.
In the ACTIV in CHF study, the long-term primary 
outcome (60 days) was worsening CHF, deﬁ  ned as death, 
CHF-related hospitalization, or unscheduled physician visit. 
There were no differences in worsening heart failure between 
the tolvaptan groups versus placebo. Tolvaptan-treated 
patients tended to require less maintenance diuretic than 
their placebo counterparts. A post hoc analysis identiﬁ  ed 
2 groups with improved 60-day mortality on tolvaptan in 
comparison with placebo. These groups were patients with 
elevated blood urea nitrogen levels (p = 0.07) and severe 
congestive symptoms (p = 0.03). Tolvaptan appeared very 
safe, with minimal side effects. There was no increased 
incidence of electrolyte abnormalities or renal failure with 
extended tolvaptan therapy. Common side effects included 
dry mouth, thirst, and urinary frequency but these were not 
statistically signiﬁ  cant compared with placebo.
In the EVEREST study, the long-term primary endpoints 
were all-cause mortality and the composite of cardiac-related 
death and hospitalization for CHF (Konstam et al 2007). 
Primary events were not different in the two groups after 
a mean follow-up time of 9.9 months. Again an increase 
in serum sodium levels was noted in patients treated with 
tolvaptan, and this increase was maintained through 40 weeks 
of therapy. The authors concluded that tolvaptan had no long-
term effect on CHF morbidity or mortality.
In the third study, Udelson et al (2005) performed a 
randomized, double-blind, placebo-controlled study of 
240 patients with CHF on standard therapy randomized to 
tolvaptan 30 mg versus placebo for 52 weeks. In addition to 
clinical outcomes, they measured LVEDV by radionuclide 
ventriculography and the plasma levels of AVP, brain 
natriuretic peptide, norepinephrine, and renin at weeks 
28 and 52. Progressive left ventricular dilatation occurs in the 
natural course of heart failure, a process that has been slowed, 
or possibly reversed, by ACE-I/ARB and beta-blocker 
therapy. Based on previous studies, it was unclear how 
tolvaptan would affect ongoing LV dilatation. On one hand, 
Gheorghiade’s earlier studies suggested a survival beneﬁ  t for 
patients receiving tolvaptan with severe congestive symptoms 
(Gheorghiade et al 2004). On the other, the question of 
unopposed V1A activity and increased AVP levels as a result 
of V2 blockade was concerning as excessive V1A receptor 
activity may contribute to cardiac myocyte hypertrophy and 
ﬁ  brosis (Costello-Boerrigter et al 2005). This could then 
lead to further dilatation of the ventricles in patients with 
CHF. Udelson et al (2005) found that there was no change in 
LVEDV in the placebo group and a non-signiﬁ  cant decrease 
(−1.8 ± 10.7 mL/m2) in tolvaptan-treated patients at the end of 
52 weeks (p = 0.21 compared with baseline LVEDV). AVP 
levels were signiﬁ  cantly elevated in the tolvaptan-treated 
Table 2 Long-term effects of tolvaptan on congestive heart failure
Study Event Tolvaptan 30 mg Placebo p value
ACTIV in CHF Death
Rehospitalization
Worsening CHF
13/239 (5.4%)
44/239 (18.4%)
64/239 (26.7%)
7/80 (8.7%)
14/80 (17.5%)
22/80 (27.5%)
0.18
0.99
0.88
EVEREST All-cause mortality
CV death or hospitalization 
for CHF
537/2063 (25.9%)
871/2063 (42.0%)
543/2055 (26.3%)
829/2055 (40.2%)
0.68
0.55
Effect of tolvaptan 
on LV dilation
Death
CHF-related hospitalizations
Post-LVEDI
6/120 (5%)
21/120 (18%)
1.78 ± 10.7
11/120 (9%)
34/120 (28%)
0.04 ± 10.0
0.03
0.21
Duration: ACTIV in CHF study: 60 days; EVEREST study: 9.9 months; and Udelson’s Effect of Tolvaptan on LV Dilation and Function: 52 weeks.
Abbreviations: CHF, congestive heart failure; CV, cardiovascular; LVEDVI, left ventricular end diastolic volume index.Therapeutics and Clinical Risk Management 2008:4(6) 1154
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arm, but no other differences in neurohormones were noted. 
During the investigation, there were 6 deaths and 21 heart 
failure-related hospitalizations in the tolvaptan group versus 
11 deaths and 34 hospitalizations in the placebo group. There 
was a signiﬁ  cant advantage of tolvaptan on mortality and 
CHF hospitalization in a time-to-event analysis (p  0.03 
by log-rank test). These secondary ﬁ  ndings contradict those 
from the ACTIV in CHF and EVEREST trials, which showed 
no long-term beneﬁ  cial effects of tolvaptan.
Synergic effects between tolvaptan 
and diuretics
In the study of Shoaf et al (2007), tolvaptan did not 
demonstrate any synergy with furosemide or HCTZ in 
healthy subjects. It should be mentioned that healthy 
subjects do not have elevated AVP levels or an activated 
renin-angiotensin-aldosterone system, therefore, the additive 
effects are likely to be limited. In patients with CHF or 
cirrhosis of the liver, these hormones are highly elevated as 
a compensatory mechanism for arterial underﬁ  lling (Schrier 
2007). Diuretics were used in 90% of patients in the 
previously described CHF studies (Gheorghiade et al 2003, 
2004, 2007; Konstam et al 2007). Clearly the addition of 
tolvaptan to diuretics in treatment arms caused an increase 
in urine output compared with placebo plus diuretics. To 
further conﬁ  rm the synergic effect, comparisons between 
tolvaptan alone versus tolvaptan plus diuretics in patients 
with CHF or cirrhosis are needed.
Choice of vaptans for cirrhosis 
and congestive heart failure
V1A + V2 receptor versus V2 blockade alone in the setting 
of CHF and cirrhosis is another clinical question that needs 
further clarification. Due to V1A blockade, conivaptan 
tends to lower systolic and diastolic blood pressures (not 
statistically signiﬁ  cant) (Ghali et al 2006). V1A receptors are 
abundant in the splanchnic circulation. In cirrhosis, a disease 
process characterized by pathologic vasodilation of this 
circulation, V1A blockade would be harmful. Theoretically, 
V2 receptor speciﬁ  c antagonists such as tolvaptan would be 
a better choice than conivaptan for treating cirrhosis-related 
hyponatremia. As for CHF, non-selective AVP antagonists 
may have advantages (Goldsmith 2007). Long-term use 
of tolvaptan is associated with an increase in endogenous 
AVP levels (Udelson et al 2005). This could potentially lead 
to unopposed V1A activation and an increase in afterload. 
Animal models have shown that myocardial cells contain 
V1A receptors and activation could trigger myocyte ﬁ  brosis 
(Costello-Boerrigter et al 2005). Per the study by Udelson 
et al (2005), there did not appear to be differences in 
ventricular structure after 1 year of therapy with tolvaptan. 
This argues against significant myocyte fibrosis with 
unopposed V1A activity. Conivaptan may be a better choice 
in CHF, but unfortunately the oral preparation has shown 
dramatic CYP3A4 inhibition, drug–drug interaction, and is 
not being developed by drug companies as a result (Ghali 
et al 2006). Clearly, trials that investigate and advantage of 
V1A + V2 receptor versus V2 blockade in CHF are needed.
Drug–drug interactions
Tolvaptan is metabolized by the CYP3A4 system and 
therefore levels of the drug could be elevated with 
coadministration of P450 inhibitors such as ketoconazole 
and amiodarone (Shoaf et al 2005). Although V2 receptor 
antagonists have less CYP3A4 interaction in comparison 
to conivaptan, the maximal plasma concentration (Cmax) 
was increased by 248%, and AUC (area under the plasma 
concentration versus time curve) 440% when tolvaptan was 
given along with ketoconazole (unpublished data). As many 
CHF patients that could beneﬁ  t from tolvaptan are also taking 
amiodarone, this is an important drug interaction to investi-
gate. Shoaf et al (2005) examined the question of interaction 
between tolvaptan and amiodarone in 2005. Patients main-
tained on oral amiodarone 200 mg daily for 10 months were 
given subsequent doses of tolvaptan (30 mg day 3, 90 mg 
day 4) while amiodarone and its metabolite desethylamoi-
darone disposition (DEA) levels were monitored. There was 
no signiﬁ  cant change in these plasma markers for pre- versus 
post-tolvaptan dosing days. Tolvaptan concentrations were 
also measured and compared with previously gathered levels 
in CHF patients. Again no signiﬁ  cant difference was noted 
in patients simultaneously receiving amiodarone. However, 
more studies are needed to determine whether long-term 
treatment with tolvaptan would have clinically signiﬁ  cant 
effects due to drug drug–interaction.
Conclusions
Vasopressin receptor antagonists have clearly been the most 
exciting medications to come forth in the nephrology ﬁ  eld for 
some time. Tolvaptan shows great promise in treating patients 
with hyponatremia. Despite minimal risk for overcorrection 
of sodium in the ﬁ  rst 24 hours, it appears to be quite safe. 
Increased thirst and dry mouth are common, but were not 
severe enough for patients to stop therapy in trials. With 
non-compliance a huge obstacle in ﬂ  uid restriction therapy, 
tolvaptan appears a better option. Patients with CHF show Therapeutics and Clinical Risk Management 2008:4(6) 1155
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increased urine output and weight loss with tolvaptan. In 
acute decompensated heart failure tolvaptan will likely be 
very helpful in ameliorating symptoms and reducing length 
of hospital stay. However, long-term improvement in CHF 
morbidity and mortality has not been proved. Once approved 
by the FDA, tolvaptan is likely to have signiﬁ  cant impact on 
clinical management of hyponatremia regardless of cause.
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